Why a disclosure of transfer of value code?
Janssen has a track record of delivering innovative and sometimes lifesaving medicines to society based on our research and our co-operation with doctors, medical scientists, hospitals and other healthcare professionals (HCPs) as well as with healthcare organisations (HCOs). This co-operation has delivered great outcomes for patients.
In June 2013, the European Federation of Pharmaceutical Industries and Associations (EFPIA) formally adopted the ‘Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations’ in an effort to further self-regulate the way pharmaceutical companies collaborate with HCPs or their organisations when value transfer (such as fees for consultancy services or educational grants) is involved.
In June 2016, Janssen along with other pharmaceutical companies who are members of EFPIA, published transfers of value made during 2015, such as financial support provided to HCPs to attend educational meetings, fees for services provided to Janssen by HCPs or educational grants to HCOs. Moving forwards, transfers of value will be published in June on an annual basis for transactions made during the previous calendar year.
At Janssen, we actively encouraged the HCPs with whom we worked to agree to disclose their individual data and were very pleased that the significant majority are doing so. Our ambition is to encourage even more HCPs to join us on our journey towards achieving greater transparency in the healthcare industry. We believe open communication about these interactions is good for everyone because it helps demonstrate that patients benefit from these interactions, in the form of more informed clinical decision-making and the appropriate use of medicines.
Janssen wholeheartedly supports the disclosure of transfers of value. The EFPIA Disclosure Code and corresponding country-level industry association codes represent an important milestone on our journey to achieving greater transparency in the way that industry and the medical community work together. These relationships are essential for furthering our understanding of disease, continuously progressing the advancement of medicines and ultimately enhancing outcomes for patients.
CP-459038
September 2024